Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash & Equivalents: 2023-2024

Historic Cash & Equivalents for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $319.7 million.

  • Zenas BioPharma's Cash & Equivalents fell 16.23% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 16.23%. This contributed to the annual value of $319.7 million for FY2024, which is 462.36% up from last year.
  • Latest data reveals that Zenas BioPharma reported Cash & Equivalents of $319.7 million as of FY2024, which was up 462.36% from $56.9 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Cash & Equivalents registered a high of $319.7 million during FY2024, and its lowest value of $56.9 million during FY2023.
  • In the last 2 years, Zenas BioPharma's Cash & Equivalents had a median value of $188.3 million in 2023 and averaged $188.3 million.
  • Data for Zenas BioPharma's Cash & Equivalents shows a peak YoY spiked of 462.36% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Cash & Equivalents (Yearly) stood at $56.9 million in 2023, then skyrocketed by 462.36% to $319.7 million in 2024.